Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. WST
stocks logo

WST

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
725.11M
+3.28%
1.503
-1.13%
759.88M
+1.74%
1.609
-13.03%
777.30M
+3.81%
1.707
-6.19%
Estimates Revision
The market is revising Upward the revenue expectations for West Pharmaceutical Services, Inc. (WST) for FY2025, with the revenue forecasts being adjusted by 2.39% over the past three months. During the same period, the stock price has changed by -3.56%.
Revenue Estimates for FY2025
Revise Upward
up Image
+2.39%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+2.68%
In Past 3 Month
Stock Price
Go Down
down Image
-3.56%
In Past 3 Month
7 Analyst Rating
up Image0
Wall Street analysts forecast WST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WST is 295.00 USD with a low forecast of 245.00 USD and a high forecast of 370.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
0 Hold
0 Sell
Strong Buy
up Image0
Current: 221.910
sliders
Low
245.00
Averages
295.00
High
370.00
up Image0
Current: 221.910
sliders
Low
245.00
Averages
295.00
High
370.00
Evercore ISI Group
Daniel Markowitz
Buy
Initiates
$275
2025-03-18
Reason
Evercore ISI Group
Daniel Markowitz
Price Target
$275
2025-03-18
Initiates
Buy
Reason
Evercore ISI initiated coverage of West Pharmaceutical with an Outperform rating and $275 price target. The bull thesis on the stock is tied to mix shift in high value components which primarily serves the biologics market where West Pharmaceutical has a roughly 90% participation rate, the analyst tells investors in a research note. Fundamentals in the biologics market are strong, enabling significant margin accretion, the firm added.
Keybanc
Paul Knight
Buy
Maintains
$470 → $325
2025-02-14
Reason
Keybanc
Paul Knight
Price Target
$470 → $325
2025-02-14
Maintains
Buy
Reason
KeyBanc analyst Paul Knight lowered the firm's price target on West Pharmaceutical to $325 from $470 to reflect lower FY25 estimates and confidence in long-term fundamentals, while keeping an Overweight rating on the shares. The firm notes West beat Q4 expectations, but the stock is down significantly due to disappointing FY25 guidance of 2%-3% organic growth vs. KeyBanc at +7.2% and the Street at 6.1%.
Citigroup
Thomas Palmer
Strong Buy
Initiates
$400
2025-01-08
Reason
Citigroup
Thomas Palmer
Price Target
$400
2025-01-08
Initiates
Strong Buy
Reason
Citi initiated coverage of West Pharmaceutical with a Buy rating and $400 price target. West is a provider of packaging and injectable solutions and services for the pharmaceutical industry, the analyst tells investors in a research note. The firm says the company is a "well-entrenched player" in the space for premium enhancements and devices, which the company labels as high value products. Citi sees "significant growth opportunities" for HVPs driven by a shift to biologics, stricter regulatory environment, and GLP-1s. Additionally, it sees "significant runway" from ongoing capacity expansions specifically geared towards higher-margin products and believes the company's near-term margin headwinds from these expansions are understood.
Wolfe Research
Doug Schenkel
Hold
Initiates
n/a
2024-12-13
Reason
Wolfe Research
Doug Schenkel
Price Target
n/a
2024-12-13
Initiates
Hold
Reason
Wolfe Research initiated coverage of West Pharmaceutical with a Peer Perform rating.
B of A Securities
Derik De Bruin
Strong Buy
Maintains
$350 → $355
2024-12-13
Reason
B of A Securities
Derik De Bruin
Price Target
$350 → $355
2024-12-13
Maintains
Strong Buy
Reason
Wolfe Research analyst Doug Schenkel initiated coverage of West Pharmaceutical with a Peer Perform rating and no price target. West Pharm is "perhaps the best-in-class" drug packaging and delivery company in the world, the analyst tells investors in a research note. The firm says that while management is highly regarded and has an extensive track record of strong operating discipline. Street estimates do not look conservative and even relative to those estimates, the shares are currently trading at 30-times estimated 2025 EBITDA. It expects continued "self funding" of capex to pressure West 's near term cash flow.
UBS
John Sourbeer
Hold
to
Strong Buy
Upgrades
$350 → $390
2024-12-12
Reason
UBS
John Sourbeer
Price Target
$350 → $390
2024-12-12
Upgrades
Hold
to
Strong Buy
Reason
UBS upgraded West Pharmaceutical to Buy from Neutral with a price target of $390, up from $350. The firm has incremental confidence in a positive mix shift driven by Annex 1 regulations, wearable injectors, and GLP-1 tailwinds, and tells investors in a research that coupled with a view that destocking headwinds should dissipate soon, the combination drives confidence West can return to long- range plan growth earlier than expected, driving stock performance.
See All Ratings

Valuation Metrics

The current forward P/E ratio for West Pharmaceutical Services Inc (WST.N) is 35.15, compared to its 5-year average forward P/E of 44.92. For a more detailed relative valuation and DCF analysis to assess West Pharmaceutical Services Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PE
44.92
Current PE
35.15
Overvalued PE
53.58
Undervalued PE
36.26

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average EV/EBITDA
29.07
Current EV/EBITDA
21.85
Overvalued EV/EBITDA
33.96
Undervalued EV/EBITDA
24.18

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Strongly Undervalued
5Y Average PS
8.32
Current PS
5.37
Overvalued PS
9.77
Undervalued PS
6.87

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 196.32% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

WST News & Events

Events Timeline

(ET)
2025-04-24
06:13:10
West Pharmaceutical CFO Bernard Birkett to step down
select
2025-04-24
06:07:59
West Pharmaceutical ups FY25 adjusted EPS view to $6.15-$6.35 from $6.00-$6.20
select
2025-04-24
06:05:20
West Pharmaceutical reports Q1 adjusted EPS $1.45, consensus $1.23
select
Sign Up For More Events
Sign Up For More Events

News

Preview
7.0
01:20 AMNewsfilter
West Pharmaceutical Services, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 7, 2025 to Discuss Your Rights – WST

  • Class Action Lawsuit Announcement: Levi & Korsinsky, LLP has initiated a class action securities lawsuit against West Pharmaceutical Services, Inc. for alleged securities fraud affecting investors from February 16, 2023, to February 12, 2025.

  • Allegations and Next Steps: The complaint claims that the company misrepresented its financial health and operational challenges, leading to significant losses for investors; affected parties have until July 7, 2025, to request lead plaintiff status without incurring costs.

Preview
7.0
06-13Newsfilter
Investors in West Pharmaceutical Services, Inc. Should Contact Levi & Korsinsky Before July 7, 2025 to Discuss Your Rights - WST

  • Class Action Lawsuit Notification: Levi & Korsinsky, LLP has announced a class action securities lawsuit against West Pharmaceutical Services, Inc. for alleged securities fraud affecting investors between February 16, 2023, and February 12, 2025.

  • Details of Allegations: The lawsuit claims that the company made misleading statements regarding its financial health and operational efficiency, particularly concerning its product demand and profit margins, which led to significant losses for investors.

Preview
7.0
06-13Globenewswire
DEADLINE ALERT for WST, DMRC, CODI, ELV: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

  • Class Action Lawsuits Filed: Several class action lawsuits have been initiated against publicly-traded companies including West Pharmaceutical Services, Digimarc Corporation, Compass Group Diversified Holdings, and Elevance Health, with deadlines for lead plaintiff motions ranging from July 7 to July 11, 2025.

  • Allegations of Misleading Statements: The complaints allege that these companies made false or misleading statements regarding their business operations and financial conditions, which misled investors about their prospects and performance during specified class periods.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is West Pharmaceutical Services Inc (WST) stock price today?

The current price of WST is 221.91 USD — it has decreased -1.33 % in the last trading day.

arrow icon

What is West Pharmaceutical Services Inc (WST)'s business?

West Pharmaceutical Services, Inc. is a global manufacturer that is engaged in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. The Company operates through two segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers packaging, containment solutions, and drug delivery products, along with analytical lab services and other integrated services and solutions, primarily to biologic, generic and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. This segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.

arrow icon

What is the price predicton of WST Stock?

Wall Street analysts forecast WST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WST is 295.00 USD with a low forecast of 245.00 USD and a high forecast of 370.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is West Pharmaceutical Services Inc (WST)'s revenue for the last quarter?

West Pharmaceutical Services Inc revenue for the last quarter amounts to 698.00M USD, increased 0.37 % YoY.

arrow icon

What is West Pharmaceutical Services Inc (WST)'s earnings per share (EPS) for the last quarter?

West Pharmaceutical Services Inc. EPS for the last quarter amounts to 1.23 USD, decreased -20.65 % YoY.

arrow icon

What changes have occurred in the market's expectations for West Pharmaceutical Services Inc (WST)'s fundamentals?

The market is revising Upward the revenue expectations for West Pharmaceutical Services, Inc. (WST) for FY2025, with the revenue forecasts being adjusted by 2.39% over the past three months. During the same period, the stock price has changed by -3.56%.
arrow icon

How many employees does West Pharmaceutical Services Inc (WST). have?

West Pharmaceutical Services Inc (WST) has 10600 emplpoyees as of June 14 2025.

arrow icon

What is West Pharmaceutical Services Inc (WST) market cap?

Today WST has the market capitalization of 15.94B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free